# Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease

> **NCT01751802** · PHASE3 · TERMINATED · sponsor: **Emalex Biosciences Inc.** · enrollment: 9 (actual)

## Conditions studied

- Lesch-Nyhan Disease
- Self-injurious Behavior

## Interventions

- **DRUG:** Ecopipam
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01751802
- **Lead sponsor:** Emalex Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-12
- **Primary completion:** 2013-12
- **Final completion:** 2014-12
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Study terminated for commercial reasons
- **Last updated:** 2024-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01751802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01751802, "Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01751802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*